文献速递淋巴瘤

阿可替尼治疗慢性淋巴细胞白血病的真实世界疗效与安全性:多中心经验

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.
PubMed 文献 · Br J Haematol · 2026-07-02

这项意大利10中心回顾性研究纳入155例CLL/SLL成人患者,评估阿可替尼单药真实世界表现。中位随访16个月,中位至停药时间未达到,总缓解率84.5%,中位OS未达到(78.7%存活),停药率20%,心血管毒性低。结论支持阿可替尼在未选择真实世界CLL患者(含 frail 老年/高危)中的持久疗效与耐受性。

要点

  • 中位随访16个月,中位至停药时间未达到,总缓解率84.5%。
  • 6个月时血红蛋白11.1-12.6 g/dL、血小板146-160×10^9/L,中性粒细胞未下降(p=0.48)。
  • 停药率20%(主要因不良事件),仅1例3级房颤,心血管毒性低。

核心结论

  • 阿可替尼在未选择的真实世界CLL患者中显示持久疗效与耐受性,含既往心血管合并症患者。
  • 结果在体弱老年/高危患者中验证了临床试验结论,支持常规治疗中广泛使用。

研究设计与样本

  • 意大利10家血液中心回顾性多中心研究(2021-2025年),评估阿可替尼单药治疗。
  • 纳入155例成人CLL/SLL患者,中位年龄74岁,44.5%≥75岁,35.5%复发/难治,59.4%心血管合并症,24.5% del17p/TP53。
  • 主要终点为至停药时间(TTD,≥28天中断/进展/死亡);次要终点包括缓解率、血液学恢复、OS和安全性。

主要发现

  • 中位TTD未达到(随访16个月),总缓解率84.5%(32.9%临床完全缓解,4例经骨髓评估强化)。
  • 中位OS未达到,78.7%存活。
  • 6个月时血红蛋白11.1-12.6 g/dL、血小板146-160×10^9/L、淋巴细胞57.5-12.3×10^9/L(p<0.001),中性粒细胞未下降(p=0.48)。
  • TTD在年龄/治疗线数/心血管合并症/生物学亚组间无差异(p>0.05)。
  • 停药率20%(主要因不良事件),心血管毒性低(1例3级房颤)。

关键数值与推荐

  • 缓解率基于国际慢性淋巴细胞白血病工作组(iwCLL)标准。
  • TTD定义为≥28天中断/进展/死亡。
  • 亚组分析年龄/线数/心血管合并症/生物学对TTD无差异(p>0.05)。

临床怎么用

  • 支持阿可替尼用于伴心血管合并症的老年CLL患者。
  • 治疗中需监测不良事件,但心血管毒性发生率低。
  • 真实世界数据支持在体弱老年/高危患者中广泛采用阿可替尼。

局限性

  • 回顾性多中心设计。
  • 中位随访仅16个月,TTD与OS中位未达到。
  • 样本来自意大利10中心,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real-world data on acalabrutinib, a second-generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy. This retrospective multicentre study evaluated acalabrutinib monotherapy across 10 Italian haematology centres (2021-2025), including 155 adults with CLL/small lymphocytic lymphoma (SLL) (median age 74 years, 44.5% ≥75 years, 35.5% relapsed/refractory, 59.4% cardiovascular comorbidities, 24.5% del17p/TP53). Primary end-point was time-to-discontinuation (TTD ≥28 days interruption/progression/death); secondary included response rates (based on International Workshop on Chronic Lymphocytic Leukemia criteria), haematological recovery, overall survival (OS) and safety. Median TTD was not reached (16 months follow-up), overall response rate 84.5% (32.9% clinical complete remission, reinforced by bone marrow evaluation in four cases), OS median not reached (78.7% alive), reporting rapid haematological recovery occurred (at 6 months haemoglobin 11.1-12.6 g/dL, platelets 146-160 × 109/L, lymphocytes 57.5-12.3 × 109/L; p < 0.001), uniform across subgroups (no TTD differences by age/line/cardiovascular comorbidities/biology; p > 0.05), without reduction of neutrophils (p = 0.48). Discontinuation was 20% (primarily due to adverse events), with low cardiovascular toxicity (one grade 3 atrial fibrillation). This study confirms acalabrutinib's durable effectiveness and tolerability in unselected real-world CLL, above in patients with prior cardiovascular comorbidities, confirming clinical trial results also in frail elderly/high-risk patients, supporting its broad adoption in routine care.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Duminuco A, Leotta D, Allegra A, et al. Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience. Br J Haematol. 2026. PMID: 42394130. doi:10.1111/bjh.70638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。